Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Fulvestrant, aromatase inhibitors, and tamoxifen
13 evidence topics · 13 sources
Guideline recommendation: NCCN, endocrine monotherapy
Guideline recommendation: NCCN, fulvestrant dose
Comparator regulatory information: fulvestrant
Comparator regulatory information: exemestane
OPERA-01 control arm: standard-of-care endocrine monotherapy
“Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm. The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant was recommended to patients who have not previously received fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm
“However, the clinical activity of endocrine monotherapy in patients who have received prior CDK4/6 or mammalian target of rapamycin inhibition is limited, with a median progression-free survival (PFS) of approximately 2 months, highlighting a major unmet clinical need in the field.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SOC treatment was per investigator's choice of fulvestrant, anastrozole, letrozole, or exemestane monotherapy and dosed according to the labeling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm in ESR1-mutated disease
Fulvestrant or exemestane: EMBER-3 control arm outcomes
“Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: VERITAC-2 control arm outcomes
“Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: CAPItello-291 control arm outcomes
“In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fulvestrant: VIKTORIA-1 control arm outcomes
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monotherapy in the second line: real-world progression-free survival
“the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote